These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 2682370)
1. [The L.A.I. test and tumor markers (Ca 19-9 and TPA) in the diagnosis of pancreatic carcinoma]. Meduri F; Bizzarini M; Diana F; Merenda R; Gerunda GE; Doni MG; Maffei Faccioli A Minerva Chir; 1989 Aug; 44(15-16):1777-81. PubMed ID: 2682370 [TBL] [Abstract][Full Text] [Related]
2. The role of the leukocyte adherence inhibition (LAI), CA 19-9, and tissue polypeptide antigen (TPA) tests in the diagnosis of pancreatic cancer. Meduri F; Doni MG; Merenda R; Bizzarini M; Neri D; Gerunda GE; Maffei Faccioli A Cancer; 1989 Sep; 64(5):1103-6. PubMed ID: 2667748 [TBL] [Abstract][Full Text] [Related]
3. [Value and limitations of neoplasm markers in the diagnosis of pancreatic carcinoma]. Fabris C; Basso D; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Ferrara C; Scalon P; Naccarato R Recenti Prog Med; 1991 Mar; 82(3):166-72. PubMed ID: 2047559 [TBL] [Abstract][Full Text] [Related]
4. [Tumor markers of pancreatic cancer]. Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615 [TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397 [TBL] [Abstract][Full Text] [Related]
6. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis]. Basso D; Fabris C; Del Favero G; Panucci A; Piccoli A; Plebani M; Pedrazzoli S; Baccaglini U; Lise M; Burlina A Minerva Med; 1986 Apr; 77(16):613-6. PubMed ID: 3458035 [TBL] [Abstract][Full Text] [Related]
7. [Tumor markers in the diagnosis of pancreatic carcinoma]. Lemma F; Bombardieri T; Salibra M; Trovato P; De Pasquale MC; Faraone V; Punturiero R; Di Mauro S Minerva Med; 1989 Jul; 80(7):645-9. PubMed ID: 2779818 [No Abstract] [Full Text] [Related]
8. [Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma]. Takahashi H; Miyazaki H; Deura M; Shimizu Y; Asukata I; Kameda H Gan No Rinsho; 1985 May; 31(6 Suppl):623-30. PubMed ID: 2411964 [TBL] [Abstract][Full Text] [Related]
9. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach. Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228 [TBL] [Abstract][Full Text] [Related]
10. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences]. Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883 [TBL] [Abstract][Full Text] [Related]
11. Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis. Basso D; Fabris C; Panucci A; Del Favero G; Angonese C; Plebani M; Petrin P; Burlina A; Naccarato R Int J Pancreatol; 1988; 3 Suppl 1():S95-100. PubMed ID: 3145303 [TBL] [Abstract][Full Text] [Related]
12. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106 [TBL] [Abstract][Full Text] [Related]
14. [Pretreatment evaluation of CA 72.4 in patients with carcinoma of the stomach (0-IV stage) versus CEA, TPA, CA 19-9, FER]. Buda F; Aragona P; Giani G; Sisto R; Di Nardo G; Binotto F; Gangemi P; De Zerbi T; Gentile G; Papadia A G Ital Oncol; 1989; 9(2-3):67-72. PubMed ID: 2767730 [TBL] [Abstract][Full Text] [Related]
15. [Serum CA 125 and TPA determination in malignant neoplasms of the uterus]. Gadducci A; Facchini V; Bartolini T; Fioretti P Ann Ostet Ginecol Med Perinat; 1988; 109(3):151-5. PubMed ID: 3207319 [No Abstract] [Full Text] [Related]
16. [Biohumeral markers in the diagnosis of pancreatic carcinoma]. Panucci A; Del Favero G; Falmis C; Brosolo P; Basso D; Pedrazzoli S; Baccaglini U; Marchioro L; Bonvilini P; Naccarato R Recenti Prog Med; 1985; 76(7-8):385-91. PubMed ID: 3865269 [No Abstract] [Full Text] [Related]
17. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study. Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729 [TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of CA 19-9 for the detection of malignant tumors--a comparison with CEA and IAP]. Furukawa M; Kazaka S; Kushibiki K; Ashida Y; Saito H; Yamamoto H; Furukawa T Gan No Rinsho; 1984 Apr; 30(4):357-62. PubMed ID: 6587133 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2]. Ohkura H; Sakawaki T Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882 [TBL] [Abstract][Full Text] [Related]